* Newstin.co.uk is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.co.uk and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.co.uk is for sale! *
Full Coverage

ACHIEVE Imaging Study Discontinued

euroinvestor.co.uk
21-May-2008
        
Story Timeline:  145 days

Merck & Co., Inc. today announced the discontinuation of ACHIEVE (An Assessment of Coronary Health Using an Intima-Media Thickness Endpoint for Vascular Effects), an imaging study evaluating MK-0524A (ER niacin/laropiprant) in patients with Heterozygous Familial Hypercholesterolemia (HeFH). The... [read full story]                    

Add Comment
Latest article on this story:

Merck ends cholesterol drug study

 pharmiweb.co.uk 23-May-2008
First article on this story:

ACHIEVE Imaging Study Discontinued

 merck.com 21-May-2008
Selected publications with coverage of this story:
foxreno.com physorg.com nbcsandiego.com nbc11.com theconservativevoice.com nbc10.com alternet.org marketwatch.com startribune.com modbee.com foxnews.com wptz.com
RELATED
Found 16 documents:

Merck ends cholesterol drug study

pharmiweb.co.uk
23-May-2008
        

Merck & Co has discontinued Achieve, an imaging study evaluating MK-0524A in patients with heterozygous familial hypercholesterolemia. The study was discontinued at the recommendation of the steering committee based on its review and evaluation of scientific data from recent carotid intima-media...

                   

Merck Can't ACHIEVE Anything

pharmiweb.co.uk
22-May-2008
        

By Brian Orelli May 22, 2008 Comments (0) What do you get when you combine a trial design that failed to show improved patient outcomes, two cholesterol-lowering drugs, and an FDA not-approvable letter? Merck (NYSE: MRK) announced yesterday that it was cancelling its ACHIEVE (An Assessment of...

Merck ends Cholesterol drug study

pharmiweb.co.uk
22-May-2008
        

Singapore, May 22, 2008: American pharma giant Merck has discontinued ACHIEVE (An Assessment of Coronary Health Using an Intima-Media Thickness Endpoint for Vascular Effects), an imaging study evaluating MK-0524A (ER niacin/laropiprant) in patients with Heterozygous Familial Hypercholesterolemia...

                   

Merck Halts Study Of Experimental Cholesterol Drug

pharmiweb.co.uk
22-May-2008
        

Co. discontinued a study of an experimental cholesterol drug after the trial's overseers concluded the patient population wasn't appropriate for the imaging technology being used to measure the drug's effectiveness. FDA also rejected Merck's proposed trade name for the product, Cordaptive, so...

                   

Health Winners & Losers: Merck

pharmiweb.co.uk
22-May-2008
        

Health stocks were down midweek amid disappointing study results and a downtrending broader market Wednesday. Merck MRK said Wednesday that it discontinued a study, dubbed Achieve, that was evaluating its MK-0524A in patients with heterozygous familial hypercholesterolemia, a genetic and severe...

Merck ends study of cholesterol drug (AP)

pharmiweb.co.uk
21-May-2008
        

By LINDA A. JOHNSON, AP Business Writer 2 hours, 7 minutes ago TRENTON, N.J. - The drugmaker said Wednesday an advisory committee recommended ending the study of cholesterol drug MK-0524A, two months after the same scientists urged enrollment of more patients be put on hold. The halted study,...

Merck Ends Cholesterol Drug Study

pharmiweb.co.uk
21-May-2008
        

— Merck & Co. has halted a study of an experimental drug it had touted as key to energizing its sagging cholesterol franchise, barely three weeks after U.S. regulators refused to allow sales of the drug. The drugmaker said Wednesday an advisory committee recommended ending the study of...

Merck Halts Cholesterol Drug Trial

pharmiweb.co.uk
21-May-2008
        

Word Count: 606 | Companies Featured in This Article: Merck, Abbott Laboratories, Schering-Plough Merck & Co. discontinued a study of an experimental cholesterol drug after the trial's overseers concluded the patient population wasn't appropriate for the imaging technology being used to measure...

Once Bitten, Merck Halts Cholesterol Drug Study

pharmiweb.co.uk
21-May-2008
        

Imagine a clinical trial of a experimental cholesterol drug that looked an awful lot like a study of a top-selling cholesterol fighter that just turned into a widely publicized debacle for your company. Now throw in the fact that the unapproved cholesterol drug you’re testing in the trial was...

2nd UPDATE: Merck Halts Cholesterol Drug Trial

pharmiweb.co.uk
21-May-2008
        

By Peter Loftus Of DOW JONES NEWSWIRES (MRK) discontinued a study of an experimental cholesterol drug after the trial's overseers concluded the patient population wasn't appropriate for the imaging technology being used to measure the drug's effectiveness. The drug is MK-524A, which was rejected...

1 2 next